TruScreen narrows 1H loss as tax credit offsets falling sales

TruScreen narrows 1H loss as tax credit offsets falling sales
Sophie Boot
By Sophie Boot Dec. 14 (BusinessDesk) - TruScreen, the NZAX-listed cervical cancer test developer, narrowed its first half loss after a decline in sales was countered by a refundable tax offset. The net loss was $352,000, or 0.2 cents per share, in the six months ended Sept. 30, from about $491,000, or 0.4 cents, a year earlier, the Auckland-based company said in a statement. Sales dropped 26 percent to $306,000. Three major customers each contributed more than 10 percent of sales in the first half, with one customer providing 56 percent...